title: Behavioral and molecular evidence for a feedback interaction between morphine and HIV-1 viral proteins.
abstract: Morphine use and addiction is common among HIV infected individuals. There is an abundance of research supporting the effects of morphine and other mu opioid receptor (MOR) ligands, on the function of HIV-1 viral proteins and progression of HIV-1 viral infection to AIDS. On the other hand, there is much less research that investigates the possible effects of the persistent presence of HIV-1 viral proteins on the expression of the MOR and the analgesic and rewarding effects of MOR ligands such as morphine. While researchers have made a great deal of progress in the past several years, the overall investigation of the interaction between opiates such as morphine and HIV-1 viral proteins is largely unilateral. It has become widely accepted that drugs of abuse interact with HIV-1 viral proteins, but the mechanisms by which this takes place are only recently being discovered. Molecular and behavioral research suggests a feedback interaction between morphine and HIV-1 viral proteins. This interaction is mediated largely by the MOR as well as interplay between MOR ligands and cytokines, chemokines and their receptors. Some of the mechanisms underlying the feedback interaction between morphine and HIV-1 viral proteins has been demonstrated using cell culture and the recently engineered HIV-1 transgenic (HIV-1Tg) rat models.
authors.affiliation: Institute of NeuroImmune Pharmacology, Seton Hall University, 400 South Orange Avenue, South Orange, NJ 07079, USA. sulie.chang@shu.edu
authors.forename: Sulie L
authors.initials: SL
authors.lastname: Chang
authors.forename: Kaitlyn P
authors.initials: KP
authors.lastname: Connaghan
mesh_terms: D000818:Animals; D001522:Behavior, Animal; D004195:Disease Models, Animal; D025461:Feedback, Physiological; D015658:HIV Infections / Q000150:complications* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism; D054298:Human Immunodeficiency Virus Proteins / Q000096:biosynthesis / Q000187:drug effects; D006801:Humans; D051379:Mice; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000150:complications* / Q000378:metabolism; D009294:Narcotics / Q000494:pharmacology*; D017450:Receptors, Opioid, mu / Q000378:metabolism*
chemical_list: D054298:Human Immunodeficiency Virus Proteins; D009294:Narcotics; D017450:Receptors, Opioid, mu; D009020:Morphine
references.citation: Immunol Invest. 2011;40(5):498-522
references.pmid: 21425908
references.citation: Neurotox Res. 2005 Oct;8(1-2):3-24
references.pmid: 16260383
references.citation: Trends Immunol. 2003 Mar;24(3):116-21
references.pmid: 12615205
references.citation: Kidney Int. 2003 Jun;63(6):2242-53
references.pmid: 12753314
references.citation: J Acquir Immune Defic Syndr. 2002 Oct 1;31 Suppl 2:S62-9
references.pmid: 12394784
references.citation: Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9271-6
references.pmid: 11481487
references.citation: Bull Math Biol. 2005 Nov;67(6):1227-51
references.pmid: 16023709
references.citation: J Immunol. 1997 Mar 15;158(6):2882-90
references.pmid: 9058825
references.citation: Brain Res Mol Brain Res. 1998 Oct 30;61(1-2):190-4
references.pmid: 9795212
references.citation: Proc Natl Acad Sci U S A. 1994 May 10;91(10):4219-23
references.pmid: 7910403
references.citation: J Neuroimmune Pharmacol. 2010 Dec;5(4):566-73
references.pmid: 20532992
references.citation: Ann N Y Acad Sci. 1995 May 10;757:353-61
references.pmid: 7611692
references.citation: Brain Res. 1999 May 22;829(1-2):174-9
references.pmid: 10350544
references.citation: Int Immunopharmacol. 2006 Sep;6(9):1459-67
references.pmid: 16846840
references.citation: Curr Pharm Des. 2005;11(14):1805-43
references.pmid: 15892677
references.citation: Pharmacol Biochem Behav. 2002 May;72(1-2):101-5
references.pmid: 11900775
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15138-43
references.pmid: 17846423
references.citation: Eur J Neurosci. 2000 Aug;12(8):2967-74
references.pmid: 10971637
references.citation: Life Sci. 1984 Jun 4;34(23):2251-5
references.pmid: 6328162
references.citation: Nat Rev Immunol. 2005 Jan;5(1):69-81
references.pmid: 15630430
references.citation: Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1680-7
references.pmid: 18784333
references.citation: J Neuroimmunol. 1998 Mar 15;83(1-2):63-9
references.pmid: 9610674
references.citation: J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S582-92
references.pmid: 12592304
references.citation: J Immunol. 1984 Jun;132(6):3046-53
references.pmid: 6327817
references.citation: Physiol Behav. 1997 Oct;62(4):905-8
references.pmid: 9284515
references.citation: Mol Immunol. 2004 Aug;41(10):979-84
references.pmid: 15302160
references.citation: J Exp Med. 1998 Jul 20;188(2):317-25
references.pmid: 9670044
references.citation: Neurochem Int. 1994 May;24(5):401-26
references.pmid: 7647696
references.citation: Ann N Y Acad Sci. 1998 May 1;840:9-20
references.pmid: 9629232
references.citation: Virology. 2006 Feb 20;345(2):373-89
references.pmid: 16289656
references.citation: Brain Res. 2002 Apr 19;933(2):98-108
references.pmid: 11931854
references.citation: Intensive Crit Care Nurs. 2001 Jun;17(3):155-66
references.pmid: 11868686
references.citation: Mol Pharmacol. 2004 Dec;66(6):1719-26
references.pmid: 15448191
references.citation: Eur J Neurosci. 1999 May;11(5):1501-7
references.pmid: 10215902
references.citation: J Neurosci. 1989 Sep;9(9):3040-57
references.pmid: 2552039
references.citation: Front Biosci (Schol Ed). 2009 Jun 01;1:164-70
references.pmid: 19482692
references.citation: J Virol. 2007 Aug;81(16):8406-11
references.pmid: 17553897
references.citation: J Pediatr. 2006 Mar;148(3):389-91
references.pmid: 16615974
references.citation: J Neuroimmunol. 2010 Jan 25;218(1-2):94-101
references.pmid: 19913921
references.citation: Drug Alcohol Depend. 2001 Apr 1;62(2):111-23
references.pmid: 11245967
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15072-7
references.pmid: 9844017
references.citation: J Neuroimmune Pharmacol. 2009 Sep;4(3):309-16
references.pmid: 19444617
references.citation: Pharmacol Biochem Behav. 2005 Nov;82(3):590-600
references.pmid: 16337260
references.citation: Pain. 2005 May;115(1-2):50-9
references.pmid: 15836969
references.citation: J Neurovirol. 2009 Jan;15(1):14-24
references.pmid: 19085205
references.citation: J Neuroimmune Pharmacol. 2007 Dec;2(4):319-28
references.pmid: 18040850
references.citation: Microbes Infect. 2006 Apr;8(5):1347-57
references.pmid: 16697675
references.citation: J Neurochem. 2010 Jul;114(1):97-109
references.pmid: 20403075
references.citation: Behav Processes. 2005 Feb 28;68(2):165-72
references.pmid: 15686826
references.citation: J Neurosci. 2004 Aug 18;24(33):7353-65
references.pmid: 15317861
references.citation: West J Med. 1998 Feb;168(2):93-7
references.pmid: 9499742
references.citation: Pain. 2000 Dec 15;89(1):39-45
references.pmid: 11113291
references.citation: Physiol Behav. 2003 Oct;80(1):19-26
references.pmid: 14568304
references.citation: J Immunol. 2002 Oct 1;169(7):3589-99
references.pmid: 12244149
references.citation: Immunopharmacology. 1998 Jan;38(3):261-6
references.pmid: 9506826
references.citation: J Neurochem. 1996 Jan;66(1):425-8
references.pmid: 8522984
references.citation: J Immunol. 2005 Jan 1;174(1):426-34
references.pmid: 15611267
references.citation: Glia. 2010 Oct;58(13):1630-9
references.pmid: 20578038
references.citation: Am J Pathol. 2010 Sep;177(3):1397-410
references.pmid: 20651230
references.citation: New Microbiol. 2005 Oct;28(4):281-97
references.pmid: 16386013
references.citation: Mol Pharmacol. 2003 Oct;64(4):876-84
references.pmid: 14500744